In the VESALIUS-CV randomized trial subgroup analysis, evolocumab added to statin therapy in high-risk patients with diabetes but without known significant atherosclerosis significantly reduced the incidence of first major cardiovascular events, achieving substantial low-density lipoprotein cholesterol reduction compared with placebo. These findings support earlier intensification of lipid-lowering therapy with proprotein convertase subtilisin/kexin type 9 inhibition in primary prevention populations, suggesting benefit beyond traditional secondary prevention strategies.

Source: JAMA